Monitoring chemokine concentrations in peripheral blood and changes in the ratio of CD4+ T and CD8+ T cells could indicate an improvement in the immune status of cancer patients, which may be useful for evaluating the efficacy of tumor treatment in the future. The gene discussed is CD8A; the disease is neoplasm.